Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15020489 | 0.80 | MAPT (0.66) | LMNAMAPTTDP1KDM4EGAA | |
| SCHEMBL3472474 | 0.80 | LMNA (0.66) | LMNAMAPTTDP1KDM4EPIK3CA | |
| SCHEMBL1245491 | 0.80 | LMNA (0.66) | LMNAMAPTTDP1KDM4EMEN1 | |
| SCHEMBL21341664 | 0.79 | MAPT (0.60) | LMNAMAPTTDP1KDM4ERAB9A | |
| SCHEMBL461478 | 0.79 | LMNA (1.00) | LMNAMAPTTDP1KDM4EGAA | |
| SCHEMBL102634 | 0.78 | LMNA (0.62) | LMNAMAPTKDM4ERAB9APIK3CA | |
| SCHEMBL16534777 | 0.78 | LMNA (0.68) | LMNAMAPTTDP1KDM4EGAA | |
| SCHEMBL24962582 | 0.76 | AKT2 (0.66) | MAPTMEN1KMT2AALOX15ALOX12 | |
| SCHEMBL4171344 | 0.76 | MAPT (0.60) | LMNAMAPTTDP1KDM4EALOX15 | |
| SCHEMBL2851246 | 0.76 | MAPT (1.00) | LMNAMAPTTDP1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111568902-B | Application of 4- (4-chlorphenyl) -1H-pyrazole-5-amine and derivatives thereof in preparation of HIV-1 expression inhibitor | 中山大学 | 2021-08-31 | — | — | CN | claimed |
| CN-111568902-A | Application of 4- (4-chlorphenyl) -1H-pyrazole-5-amine and derivatives thereof in preparation of HIV-1 expression inhibitor | 中山大学 | 2020-08-25 | — | — | CN | claimed |
| CN-111568902-B | Application of 4- (4-chlorphenyl) -1H-pyrazole-5-amine and derivatives thereof in preparation of HIV-1 expression inhibitor | 中山大学 | 2021-08-31 | — | — | CN | disclosed |
| CN-111568902-B | Application of 4- (4-chlorphenyl) -1H-pyrazole-5-amine and derivatives thereof in preparation of HIV-1 expression inhibitor | 中山大学 | 2021-08-31 | — | — | CN | disclosed |
| CN-111568902-B | Application of 4- (4-chlorphenyl) -1H-pyrazole-5-amine and derivatives thereof in preparation of HIV-1 expression inhibitor | 中山大学 | 2021-08-31 | — | — | CN | disclosed |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| CN-111568902-A | Application of 4- (4-chlorphenyl) -1H-pyrazole-5-amine and derivatives thereof in preparation of HIV-1 expression inhibitor | 中山大学 | 2020-08-25 | — | — | CN | disclosed |
| CN-111568902-A | Application of 4- (4-chlorphenyl) -1H-pyrazole-5-amine and derivatives thereof in preparation of HIV-1 expression inhibitor | 中山大学 | 2020-08-25 | — | — | CN | disclosed |
| CN-111568902-A | Application of 4- (4-chlorphenyl) -1H-pyrazole-5-amine and derivatives thereof in preparation of HIV-1 expression inhibitor | 中山大学 | 2020-08-25 | — | — | CN | disclosed |
| EP-3215505-B1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma AG (DE) | 2019-07-24 | — | — | EP | disclosed |
| WO-2011014520-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-02-03 | — | — | WO | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| CN-101808666-A | Combination of antimitotic and lasokinase inhibitors as anticancer therapy | SCHERING CORP | 2010-08-18 | — | — | CN | disclosed |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-05-27 | — | — | US | disclosed |
| EP-2182986-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2010-05-12 | — | — | EP | disclosed |
| CN-101568527-A | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | SCHERING CORP (US) | 2009-10-28 | — | — | CN | disclosed |
| EP-2078004-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008054749-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | LMNA 1510/4885MAPT 1628/4885TDP1 527/4885 |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MAPK15, CDK15, MAP3K15 | LMNA 3441/4885MAPT 469/4885TDP1 1581/4885 |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | PASK, PDXK, PANK2 | LMNA 1114/4885MAPT 3629/4885TDP1 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.